Monitoring biomarkers of cellular injury and death in acute brain injury.
Monitoring biomarkers of cellular injury and death in acute brain injury.
复制标题
DOI：
10.1007/s12028-014-0039-z
复制
发表时间：
2014-12
影响因子：
3.5
通讯作者：
Participants in the International Multi-disciplinary Consensus Conference on the Multimodality Monitoring
中科院分区：
文献类型：
--
作者：
Chou SH;Robertson CS;Participants in the International Multi-disciplinary Consensus Conference on the Multimodality Monitoring
分子生物标志物已经彻底改变了许多疾病的诊断和治疗，例如肌钙蛋白在心肌梗死中的应用。神经危重症护理对高保真度生物标志物的迫切需求导致许多研究报告了潜在的候选生物标志物。我们对成人急性缺血性卒中（AIS）、脑出血（ICH）、蛛网膜下腔出血（SAH）、外伤性脑损伤（TBI）和心脏骤停后缺氧缺血性脑病损伤（HIE）患者的预后和疾病特异性继发性并发症相关的细胞/分子生物标志物进行了电子文献检索和系统综述。共纳入135篇文章。虽然已经确定了各种各样的潜在生物标志物，但只有神经元特异性烯醇化酶已在大型队列中得到验证，并且在未接受治疗性低温治疗的HIE患者中显示出100%的特异性，用于不良预后预测。在SAH、AIS、ICH和TBI中有许多有希望的候选血液和脑脊液生物标志物，但尚未达到常规临床使用的标准。目前的研究在患者选择、生物样本收集/处理和生物标志物测量方案方面存在显著差异，从而限制了总体结果的普遍性。未来有必要进行标准化治疗、生物样本收集、生物标志物测量和验证方案的大型前瞻性研究，以确定神经危重症护理中的高保真生物标志物。
Molecular biomarkers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction. Urgent need for high-fidelity biomarkers in neurocritical care has resulted in numerous studies reporting potential candidate biomarkers. We performed an electronic literature search and systematic review of English language articles on cellular/molecular biomarkers associated with outcome and with disease-specific secondary complications in adult patients with acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), and post-cardiac arrest hypoxic ischemic encephalopathic injuries (HIE). A total of 135 articles were included. Though a wide variety of potential biomarkers have been identified, only neuron-specific enolase has been validated in large cohorts and shows 100 % specificity for poor outcome prediction in HIE patients not treated with therapeutic hypothermia. There are many promising candidate blood and CSF biomarkers in SAH, AIS, ICH, and TBI, but none yet meets criteria for routine clinical use. Current studies vary significantly in patient selection, biosample collection/processing, and biomarker measurement protocols, thereby limiting the generalizability of overall results. Future large prospective studies with standardized treatment, biosample collection, and biomarker measurement and validation protocols are necessary to identify high-fidelity biomarkers in neurocritical care.
登录
查看更多内容
影响因子：
8.3
作者：
Chou SH;Lee PS;Konigsberg RG;Gallacci D;Chiou T;Arai K;Simmons S;Bauer D;Feske SK;Lo EH;Ning M
通讯作者：
Ning M
影响因子：
8.3
作者：
Castellanos, Mar;Sobrino, Tomas;Davalos, Antoni
通讯作者：
Davalos, Antoni
影响因子：
4.1
作者：
Abilleira, S;Montaner, J;Alvarez-Sabín, J
通讯作者：
Alvarez-Sabín, J
影响因子：
4.1
作者：
Berger, RP;Adelson, PD;Kochanek, PM
通讯作者：
Kochanek, PM
影响因子：
4.2
作者：
Brophy, Gretchen M.;Mondello, Stefania;Wang, Kevin K. W.
通讯作者：
Wang, Kevin K. W.